Maat Pharma · EURONEXT:MAAT
Maat Pharma — Investor Presentation (March 2026)
28 slides from Maat Pharma's investor presentation, March 2026
Slide 1: Boosting Survival Through Innovative Immune Modulation
Boosting Survival Through Innovative Immune Modulation March 2026
Slide 2: Disclaimer
MaaT Pharma March 2026 2 Disclaimer This document has been prepared by MaaT Pharma (the "Company") The information contained in this document has not been subject to This document contains certain forward -looking statements . These and is for information and background purposes only . independent v
Slide 3: Company Overview
Company Overview
Slide 4: MaaT013 (Xervyteg) in aGvHD: Achieved All Endpoints of ARES Study
MaaT Pharma March 2026 4 MaaT013 ( Xervyteg ®) in aGvHD : Achieved All Endpoints of ARES Study Registration in Europe Will Spearhead Microbiome Therapies in Oncology Xervyteg ® Moving Closer to Multi -Assets Platform Financial Commercial Readiness Focused on Oncology Overview Cash position of €24.9
Slide 5: Leveraging Microbiome Modulation in Oncology: Mechanisms for Enhanced Survival Outcomes
MaaT Pharma March 2026 5 Leveraging Microbiome Modulation in Oncology: Mechanisms for Enhanced Survival Outcomes in Multiple Settings Expected benefits Xervyteg ® ( MaaT013) Resolution Control of inflammation and restoration of gut of aGvHD integrity and production of functional metabolites Restorat
Slide 6: Oncology-Focused Platform Fueling a Deep Pipeline of Drug Candidates
MaaT Pharma March 2026 6 Oncology -Focused Platform Fueling a Deep Pipeline of Drug Candidates Native Ecosystem Co -cultured Ecosystem Integrated Production Driving near -term value Progressing next -generation donor - Leading capabilities in full ecosystem with the donor -derived MET -N platform in
Slide 7: A Strong Pipeline With Multiple Value Inflection Milestones and a Close-to-Market Asset
MaaT Pharma March 2026 7 A Strong Pipeline With Multiple Value Inflection Milestones and a Close -to-Market Asset Recent or Upcoming Indication Program Indication Market potential PRCL Ph. 1 Ph. 2 Ph. 3 MAA Status milestones Positive EU MAA under review Xervyteg ® ARES US readiness 1L : 11k patients
Slide 8: Xervyteg in aGvHD
Xervyteg ® in aGvHD
Slide 9: 3L aGvHD: ~70% 1-yr mortality, no approved therapies, ~3k EU/US pts/yr
Xervyteg ® • aGvHD → Salvage → Salvage ODD ODD EMA/FDA MaaT Pharma EMA/FDA → Quick action → Quick action March 2026 9 3L aGvHD : ~70% 1-yr mortality, no approved therapies, ~3k EU/US pts/yr Donor immune cells recognize the recipient’s tissues as Treatment Paradigm in aGvHD foreign , leading to an im
Slide 10: Xervyteg: A Standardized Allogeneic Microbiota Pooled Medicine Currently Under Review by the EMA
Xervyteg ® • aGvHD → Salvage → Salvage ODD ODD EMA/FDA MaaT Pharma EMA/FDA → Quick action → Quick action March 2026 10 Xervyteg ®: A Standardized Allogeneic Microbiota Pooled Medicine Currently Under Review by the EMA ✓ Full ecosystem ✓ High -diversity (including richness) Characteristics: 01 alloge
Slide 11: ARES: a Completed Pivotal Trial Exploring Xervyteg in 3L aGvHD
Xervyteg ® • aGvHD → Salvage → Salvage ODD ODD EMA/FDA MaaT Pharma EMA/FDA → Quick action → Quick action March 2026 11 ARES: a Completed Pivotal Trial Exploring Xervyteg ® in 3L aGvHD Milestones: Topline results in January 8 th , 2025 I EMA MAA filed on June 2 nd , 2025 I Final results in December 8
Slide 12: ARES in aGvHD in 3L: Primary Endpoint Met with Significant Day-28 GI-ORR
Xervyteg ® • aGvHD → Salvage ODD EMA/FDA MaaT Pharma → Quick action March 2026 12 ARES in aGvHD in 3L: Primary Endpoint Met with Significant Day -28 GI -ORR; Responses Sustained Through Month 3 D28 Response Rate (%)* Final Results (n=66) “ These results confirm that Xervyteg ® offers a durable 80 80
Slide 13: ARES: Higher Observed Overall Survival vs Best Available Therapy in Third-Line
Xervyteg ® • aGvHD → Salvage ODD EMA/FDA MaaT Pharma → Quick action March 2026 13 ARES: Higher Observed Overall Survival vs Best Available Therapy (BAT) in Third -Line Overall Survival, ARES Overall Survival by D28 Response Overall Survival (%) Overall Survival (%) 100 Day 28 GI-Responders Day 28 GI
Slide 14: MaaT033 in allo-HSCT
MaaT033 in allo-HSCT ee @e @ @ee8e98e#8e#es#se28ess #®
Slide 15: Phoebus (MaaT033) - Phase 2b Randomized, Double-Blinded, Placebo-Controlled Study in Allo-HSCT
MaaT033 • Allo -HSCT → Ambulatory ODD EMA MaaT Pharma → Adjunctive March 2026 15 Phoebus (MaaT033) - Phase 2b, Randomized (1:1), Double -Blinded, Placebo -Controlled Study in Allo -HSCT Visit 1 Visit 2 15 – 21 days Visit 3 Visit 6 Visit 10 D -21 D -7 D -0 Neutrophil recovery D+21 M+3 M+12 Pre Allo -
Slide 16: Commercial and Distribution Strategy in Hemato-Oncology
Commercial And Distribution Strategy in Hemato - Oncology
Slide 17: Leadership in Hemato-Oncology Across the Full Care Continuum of HSCT
MaaT Pharma March 2026 17 Leadership in Hemato -Oncology Across the Full Care Continuum of HSCT Unique Value Proposition A Significant Market Opportunity Unique immunosuppressant -sparing, microbiome -based treatment option in aGvHD ~250M € 1 ~500M € 1 Well defined target population for both product
Slide 18: Licensing Late-Stage Asset Xervyteg to Clinigen for Commercialization in Europe
MaaT Pharma March 2026 18 Licensing Late -Stage Asset Xervyteg ® to Clinigen for Commercialization in Europe* • Leading position in hospital distribution • Recognized expertise in critical care ~75 -100M € • Hemato -Oncology Portfolio in Europe • Extended network of prescribers • Specialist in Early
Slide 19: Bringing Xervyteg to Market: Financial terms of the Commercial Partnership for Europe
MaaT Pharma March 2026 19 Bringing Xervyteg ® to Market: Financial terms of the Commercial Partnership for Europe Financial Terms Upfront payment MAA milestone Sales milestones Royalties on net sales Drug Supply 10.5M€ 12M€ 6M € Mid -thirties Set C ost Terms European Market for X ervyteg ® Total Adr
Slide 20: Early Access Program in Europe Now Transitioned to Clinigen
MaaT Pharma March 2026 20 Early Access Program in Europe Now Transition ed to Clinigen Supplying The Increasing International Demand Clinical Outcomes (Real World Evidences) Number of patients • 173 GvHD patients analyzed as of October 2024 and +24% presented at EHA 2025 : • Efficacy (All lines) = G
Slide 21: Largest European cGMP Manufacturing Facility for Microbiome Ecosystem Therapies
→ cGMP → Scalable MaaT Pharma Largest European cGMP Manufacturing Facility for Microbiome Ecosystem Therapies TM Xervyteg ® 11,000 3,500 Leading microbiome therapies fully integrated manufacturing MaaT033 1,300,000 6,000 and development platform: streamlined product development, scaleup and GMP proc
Slide 22: Future Growth Drivers in Immuno-Oncology
Future Growth Drivers in Immuno - Oncology
Slide 23: ICI Primary Resistance, an Unmet Need for Patient with Advanced Cancers
→ ICI MaaT034 MaaT034 ••IOIO–-Solid Melanoma Tumors MaaT Pharma → Combo March 2026 23 ICI Primary Resistance, an Unmet Need for Patient with Advanced Cancers Primary Resistance Rate to Immune Checkpoint Around 19 million people diagnosed with cancer 01 Inhibitors each year globally Immune Checkpoint
Slide 24: From Proof to Platform: An Integrated IO Approach
MaaT Pharma March 2026 24 From Proof to Platform: An Integrated IO Approach MET -C platform will lead the Company’s IO strategy 2 MET -N MET -C 1 Xervyteg ® - MaaT033 MaaT03X Full High Diversity Microbiome -based Rationally Selected Targeted Metabolite Synergies with Enhancement/ Ecosystem Pivotal T
Slide 25: Looking Ahead & Key Takeaways
Looking Ahead & Key Takeaways
Slide 26: Several Major Near-Term Value Inflection Expected Milestones
MaaT Pharma March 2026 26 Several Major Near -Term Value Inflection Expected Milestones 2025 2026 2027 2028 Partnered ® I GvHD Xervyteg ® Xervyteg Xervyteg ® Ares Ph3 D28 GI -ORR results GvHD | MA potential decision GvHD | Potential Pivotal Ph3*in Jan 25 EMA mid 26 the US FPI 27 MA application EMA J
Slide 27: Corporate Social Responsibility
MaaT Pharma March 2026 27 Corporate Social Responsibility MaaT Pharma is a leading, late -stage clinical Patients are the priority. MaaT Pharma is committed → Innovate and raise awareness to deliver Company committed to advancing gut to patients and to the protection of human health by better care,
Slide 28: Thank you
Thank you